Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it

References

• Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21(6):897–903. doi: 10.1023/B:PHAM.0000029275.41323.a6. PMID: 15212151.
   PubMed Web of Science ®Google Scholar
• Scott D, De Groot A. Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis. 2010;69(Suppl 1):i72–i6. doi: 10.1136/ard.2009.117564. PMID: 19995750.
   PubMed Web of Science ®Google Scholar
• Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006;24(6):274–80. doi: 10.1016/j.tibtech.2006.04.001. PMID: 16631266.
   PubMed Web of Science ®Google Scholar
• Baker M, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/Nonself. 2010;1(4):314–22. doi: 10.4161/self.1.4.13904. PMID: 21487506.
   PubMedGoogle Scholar
• Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555–61. doi: 10.1038/nbt1303. PMID: 17483842.
   PubMed Web of Science ®Google Scholar
• Food Administration D. Guidance for industry, immunogenicity assessment for therapeutic protein products. 2014. 2015.
   Google Scholar
• De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discovery Dev. 2007;10(3):332.
   PubMedGoogle Scholar
• Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med. 1993;177(3):627–36. doi: 10.1084/jem.177.3.627. PMID: 8094734.
   PubMed Web of Science ®Google Scholar
• Reijonen H, Novak EJ, Kochik S, et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002;51(5):1375–82. doi: 10.2337/diabetes.51.5.1375. PMID: 11978633.
   PubMed Web of Science ®Google Scholar
• Forsthuber TG, Shive CL, Wienhold W, et al. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1* 0401) transgenic mice are encephalitogenic and are presented by human B cells. J Immunol. 2001;167(12):7119–25. doi: 10.4049/jimmunol.167.12.7119. PMID: 11739534.
   PubMed Web of Science ®Google Scholar
• Keech CL, Farris AD, Beroukas D, et al. Cognate T cell help is sufficient to trigger anti-nuclear autoantibodies in naive mice. J Immunol. 2001;166(9):5826–34. doi: 10.4049/jimmunol.166.9.5826. PMID: 11313427.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720–40. doi: 10.1016/S0149-2918(02)80075-3. PMID: 12501870.
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Friesen H-J, Frodin J-E, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994;84(12):4078–87. PMID: 7994026.
   PubMed Web of Science ®Google Scholar
• LeMaoult J, Szabo P, Weksler ME. Effect of age on humoral immunity, selection of the B‐cell repertoire and B‐cell development. Immunol Rev. 1997;160(1):115–26. doi: 10.1111/j.1600-065X.1997.tb01032.x. PMID: 9476670.
   PubMedGoogle Scholar
• PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol. 2011;12(3):189. doi: 10.1038/ni0311-189. PMID: 21321588.
   PubMed Web of Science ®Google Scholar
• Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. Am J Perinatol. 2013;30(2):105. doi: 10.1055/s-0032-1333412. PMID: 23297181.
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428–36. doi: 10.1038/ni.2588. PMID: 23598398.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. Considering host-specific and product-specific factors impacting immunogenicity. Biopharm Int. 2004;17(12):34–42.
   Web of Science ®Google Scholar
• Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1∗ 0401 and HLA-DRB1∗ 0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Human Genet. 2008;83(2):219–27. doi: 10.1016/j.ajhg.2008.07.006.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Dickensheets H, O'Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011;32(9):443–50. doi: 10.1016/j.it.2011.07.002. PMID: 21820962.
   PubMed Web of Science ®Google Scholar
• Weigle WO. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv Immunol. 1980;30:159. doi: 10.1016/S0065-2776(08)60196-0. PMID: 6160739.
   PubMedGoogle Scholar
• Goodnow CC. Transgenic mice and analysis of B-cell tolerance. Annu Rev Immunol. 1992;10(1):489–518. doi: 10.1146/annurev.iy.10.040192.002421. PMID: 1590994.
   PubMedGoogle Scholar
• Haribhai D, Engle D, Meyer M, et al. A threshold for central T cell tolerance to an inducible serum protein. J Immunol. 2003;170(6):3007–14. doi: 10.4049/jimmunol.170.6.3007. PMID: 12626554.
   PubMed Web of Science ®Google Scholar
• Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1):1–9. doi: 10.1016/j.jim.2008.01.001. PMID: 18275969.
   PubMed Web of Science ®Google Scholar
• Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360(16):1618–27. doi: 10.1056/NEJMoa075760. PMID: 19369668.
   PubMed Web of Science ®Google Scholar
• Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost. 2009;102(1):15–24. PMID: 19572062.
   PubMed Web of Science ®Google Scholar
• Singh SK. Impact of product‐related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354–87. doi: 10.1002/jps.22276. PMID: 20740683.
   PubMed Web of Science ®Google Scholar
• Dalum I, Jensen MR, Gregorius K, et al. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol Immunol. 1997;34(16):1113–20. doi: 10.1016/S0161-5890(97)00147-8. PMID: 9566759.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, et al. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci. 2013;34(10):534–48. doi: 10.1016/j.tips.2013.08.005. PMID: 24060103.
   PubMed Web of Science ®Google Scholar
• Huang L, Lu J, Wroblewski VJ, et al. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem. 2005;77(5):1432–9. doi: 10.1021/ac0494174. PMID: 15732928.
   PubMed Web of Science ®Google Scholar
• Demeule B, Gurny R, Arvinte T. Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates. Eur J Pharm Biopharm. 2006;62(2):121–30. doi: 10.1016/j.ejpb.2005.08.008. PMID: 16221544.
   PubMed Web of Science ®Google Scholar
• Makrygiannakis D, af Klint E, Lundberg IE, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis. 2006;65(9):1219–22. doi: 10.1136/ard.2005.049403. PMID: 16540548.
   PubMed Web of Science ®Google Scholar
• Dintzis RZ, Okajima M, Middleton M, et al. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol. 1989;143(4):1239–44. PMID: 2473123.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993;262(5138):1448–51. doi: 10.1126/science.8248784. PMID: 8248784.
   PubMed Web of Science ®Google Scholar
• Seong S-Y, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4(6):469–78. doi: 10.1038/nri1372. PMID: 15173835.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Hokom M, Eakin C, et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012;287(30):25266–79. doi: 10.1074/jbc.M111.330902. PMID: 22584577.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med. 2008;358(11):1109–17. doi: 10.1056/NEJMoa074943. PMID: 18337601.
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Taylor RE, Padler-Karavani V, et al. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28(8):863–7. doi: 10.1038/nbt.1651. PMID: 20657583.
   PubMed Web of Science ®Google Scholar
• Bretthauer RK, Castellino FJ. Glycosylation of Pichia pastoris‐derived proteins. Biotechnol Appl Biochem. 1999;30(3):193–200. PMID: 10574687.
   PubMedGoogle Scholar
• Gomord V, Faye Lc. Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol. 2004;7(2):171–81. doi: 10.1016/j.pbi.2004.01.015. PMID: 15003218.
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422(6929):307–12. doi: 10.1038/nature01470. PMID: 12646921.
   PubMed Web of Science ®Google Scholar
• Cole KS, Steckbeck JD, Rowles JL, et al. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol. 2004;78(3):1525–39. doi: 10.1128/JVI.78.3.1525-1539.2004. PMID: 14722307.
   PubMed Web of Science ®Google Scholar
• Inada Y, Furukawa M, Sasaki H, et al. Biomedical and biotechnological applications of PEG-and PM-modified proteins. Trends Biotechnol. 1995;13(3):86–91. doi: 10.1016/S0167-7799(00)88912-X. PMID: 7766222.
   PubMed Web of Science ®Google Scholar
• Liu Y, Reidler H, Pan J, et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J Pharmacol Toxicol Methods 2011;64(3):238–45. doi: 10.1016/j.vascn.2011.07.003. PMID: 21827863.
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Wang V. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PloS one 2010;5(12):e15252. doi: 10.1371/journal.pone.0015252. PMID: 21203556.
   PubMed Web of Science ®Google Scholar
• Rhee EG, Blattman JN, Kasturi SP, et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol. 2011;85(1):315–23. doi: 10.1128/JVI.01597-10. PMID: 20962088.
   PubMed Web of Science ®Google Scholar
• Eon‐Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012;28(3):608–22. doi: 10.1002/btpr.1548. PMID: 22473974.
   PubMed Web of Science ®Google Scholar
• Kwissa M, Nakaya HI, Oluoch H, Pulendran B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 2012;119(9):2044–55. doi: 10.1182/blood-2011-10-388579. PMID: 22246032.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327(5963):291–5. doi: 10.1126/science.1183021. PMID: 20075244.
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709–18. doi: 10.1056/NEJMoa053007. PMID: 16481638.
   PubMed Web of Science ®Google Scholar
• Tovey MG, Lallemand C. Adjuvant activity of cytokines. Vaccine Adjuvants: Methods Protoc. 2010:287–309. doi: 10.1007/978-1-60761-585-9_19.
   Google Scholar
• Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol. 1999;17(2):529–. doi: 10.1200/JCO.1999.17.2.529. PMID: 10080596.
   PubMed Web of Science ®Google Scholar
• Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533–44. doi: 10.1038/nri2356. PMID: 18551128.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482–90. doi: 10.1016/j.it.2007.07.011. PMID: 17964218.
   PubMed Web of Science ®Google Scholar
• Jaber A, Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal. 2007;43(4):1256–61. doi: 10.1016/j.jpba.2006.10.023. PMID: 17118612.
   PubMed Web of Science ®Google Scholar
• Kamate C, Lenting P, Van Den Berg H, Mutis T. Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII‐specific T‐cell responses in healthy individuals. J Thromb Haemostasis 2007;5(3):611–3. doi: 10.1111/j.1538-7836.2007.02336.x.
   PubMed Web of Science ®Google Scholar
• Lazarski CA, Chaves FA, Jenks SA, et al. The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity 2005;23(1):29–40. doi: 10.1016/j.immuni.2005.05.009. PMID: 16039577.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Berzofsky JA. From genome to vaccine—new immunoinformatics tools for vaccine design. Methods 2004;34(4):425–8. doi: 10.1016/j.ymeth.2004.06.004. PMID: 15542367.
   PubMed Web of Science ®Google Scholar
• Van Walle I, Gansemans Y, Parren PW, et al. Immunogenicity screening in protein drug development. Expert Opin Biol Ther. 2007;7(3):405–18. doi: 10.1517/14712598.7.3.405. PMID: 17309332.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Humbert M, Benz A, Dietrich U. 3D‐Epitope‐Explorer (3DEX): Localization of conformational epitopes within three‐dimensional structures of proteins. J Comput Chem. 2005;26(9):879–87. doi: 10.1002/jcc.20229. PMID: 15834923.
   PubMed Web of Science ®Google Scholar
• Kulkarni-Kale U, Bhosle S, Kolaskar AS. CEP: a conformational epitope prediction server. Nucleic Acids Res. 2005;33(suppl 2):W168–W71. doi: 10.1093/nar/gki460. PMID: 15980448.
   PubMedGoogle Scholar
• Batori V, Friis EP, Nielsen H, Roggen EL. An in silico method using an epitope motif database for predicting the location of antigenic determinants on proteins in a structural context. J Mol Recognit. 2006;19(1):21–9. doi: 10.1002/jmr.752. PMID: 16193533.
   PubMed Web of Science ®Google Scholar
• Greenbaum JA, Andersen PH, Blythe M, et al. Towards a consensus on datasets and evaluation metrics for developing B‐cell epitope prediction tools. J Mol Recognit. 2007;20(2):75–82. doi: 10.1002/jmr.815. PMID: 17205610.
   PubMed Web of Science ®Google Scholar
• Klitgaard JL, Coljee VW, Andersen PS, et al. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses. J Immunol. 2006;177(6):3782–90. doi: 10.4049/jimmunol.177.6.3782. PMID: 16951339.
   PubMed Web of Science ®Google Scholar
• Kong Y, Lomo LC, Motte RW, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1* 0301 (DR3) gene. J Exp Med. 1996;184(3):1167–72. doi: 10.1084/jem.184.3.1167. PMID: 9064334.
   PubMed Web of Science ®Google Scholar
• Pan S, Trejo T, Hansen J, Smart M, David CS. HLA-DR4 (DRB1* 0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response. J Immunol. 1998;161(6):2925–9. PMID: 9743354.
   PubMed Web of Science ®Google Scholar
• Shirai M, Arichi T, Nishioka M, et al. CTL responses of HLA-A2. 1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2. 1. J Immunol. 1995;154(6):2733–42. PMID: 7533182.
   PubMed Web of Science ®Google Scholar
• Man S, Newberg MH, Crotzer VL, et al. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2. 1 transgenic mice. Int Immunol. 1995;7(4):597–605. doi: 10.1093/intimm/7.4.597. PMID: 7547687.
   PubMed Web of Science ®Google Scholar
• Stewart T, Hollingshead P, Pitts S, et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med. 1989;6(4):275–81. PMID: 2482920.
   PubMedGoogle Scholar
• Zwickl C, Cocke K, Tamura R, et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam Appl Toxicol. 1991;16(2):275–87. doi: 10.1016/0272-0590(91)90112-H. PMID: 2055359.
   PubMedGoogle Scholar
• Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm Res. 1997;14(10):1472–8. doi: 10.1023/A:1012193326789. PMID: 9358564.
   PubMed Web of Science ®Google Scholar
• Ottesen J, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994;37(12):1178–85. doi: 10.1007/BF00399790. PMID: 7895946.
   PubMed Web of Science ®Google Scholar
• Palleroni A, Aglione A, Labow M, et al. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res. 1997;17:S23–7.
   PubMed Web of Science ®Google Scholar
• Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics. 2010;11(1):180. doi: 10.1186/1471-2105-11-180. PMID: 20380721.
   PubMedGoogle Scholar
• Cantor JR, Yoo TH, Dixit A, et al. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Nat Acad Sci. 2011;108(4):1272–7. doi: 10.1073/pnas.1014739108. PMID: 21209329.
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens LP, Awwad M, et al. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534–55. doi: 10.1016/j.clim.2013.09.006. PMID: 24263283.
   PubMed Web of Science ®Google Scholar
• Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep. 2001;3(1):30–7. doi: 10.1007/s11894-001-0038-z. PMID: 11177692.
   PubMedGoogle Scholar
• Cobbold S, Qin S, Waldmann H, editors. Reprogramming the immune system for tolerance with monoclonal antibodies. Sem Immunol: 1990.
   Google Scholar
• Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol. 2004;173(7):4715–23. doi: 10.4049/jimmunol.173.7.4715. PMID: 15383608.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011;7(3):341–8. doi: 10.1586/eci.11.10. PMID: 21595600.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(2):247–55. doi: 10.1007/s12016-011-8278-7. PMID: 21732045.
   PubMed Web of Science ®Google Scholar
• Dykes A, Walker I, Lowe G, Tait R. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2‐year review. Haemophilia 2001;7(2):160–3. doi: 10.1046/j.1365-2516.2001.00489.x. PMID: 11260275.
   PubMed Web of Science ®Google Scholar
• Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol. 2009;82(s71):8–12. doi: 10.1111/j.1600-0609.2008.01207.x.
   Google Scholar
• Cines DB, Liebman H, Stasi R, editors. Pathobiology of secondary immune thrombocytopenia. In: Seminars in Hematology. Elsevier; 2009.
   Google Scholar
• Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. 2009;360(2):194–5. doi: 10.1056/NEJMc0806809. PMID: 19129538.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”. Blood 2008;112(8):3303–11. doi: 10.1182/blood-2008-02-138073. PMID: 18660382.
   PubMed Web of Science ®Google Scholar
• Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol. 2013;94(2):377–83. doi: 10.1189/jlb.0912441. PMID: 23729499.
   PubMed Web of Science ®Google Scholar
• Cousens LP, Su Y, McClaine E, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res. 2013;2013. doi: 10.1155/2013/621693. PMID: 23710469.
   PubMedGoogle Scholar
• van der Marel S, Majowicz A, Kwikkers K, et al. Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World J Gastroenterol. 2012;18(32):4288–99. doi: 10.3748/wjg.v18.i32.4288. PMID: 22969191.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013;122(1):23–36. doi: 10.1182/blood-2013-01-306647. PMID: 23596044.
   PubMed Web of Science ®Google Scholar
• Moise L, Song C, Martin WD, et al. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol. 2012;142(3):320–31. doi: 10.1016/j.clim.2011.11.010. PMID: 22222093.
   PubMed Web of Science ®Google Scholar
• Holgate R, Baker MP. Circumventing immunogenicity in the development of therapeutic antibodies. IDrugs 2009;12(4):233–7. PMID: 19350467.
   PubMedGoogle Scholar
• Jones TD, Crompton LJ, Carr FJ, Baker MP. Deimmunization of monoclonal antibodies. Ther Antibodies: Methods Protoc. 2009:405–23. doi: 10.1007/978-1-59745-554-1_21.
   Google Scholar
• De Groot AS, Goldberg M, Moise L, Martin W. Evolutionary deimmunization: an ancillary mechanism for self-tolerance? Cell Immunol. 2006;244(2):148–53. doi: 10.1016/j.cellimm.2007.02.006. PMID: 17445787.
   PubMed Web of Science ®Google Scholar
• Kolkman JA, Stemmer WP. Directed evolution of proteins by exon shuffling. Nat Biotechnol. 2001;19(5):423–8. doi: 10.1038/88084. PMID: 11329010.
   PubMed Web of Science ®Google Scholar